Story perspectives

CRISPR Revolutionizes Cancer Treatment with In Vivo CAR-T Cells

3/18/2026

Summary

Story summary

A Nature study published March 18, 2026, reports that the CRISPR-Cas9 gene-editing system could enable engineering of cancer-fighting immune cells directly inside the human body.
The approach could make CAR-T therapies safer, cheaper, and easier to administer.
Current CAR-T treatments require costly manufacturing and chemotherapy pretreatments.
Researchers are testing in vivo CAR-T cell treatments in early clinical trials.
Safety concerns include unintended mutations and ensuring only T cells are edited.

1 of 1

Story summary

A Nature study published March 18, 2026, reports that the CRISPR-Cas9 gene-editing system could enable engineering of cancer-fighting immune cells directly inside the human body.
The approach could make CAR-T therapies safer, cheaper, and easier to administer.
Current CAR-T treatments require costly manufacturing and chemotherapy pretreatments.
Researchers are testing in vivo CAR-T cell treatments in early clinical trials.
Safety concerns include unintended mutations and ensuring only T cells are edited.